BridgeBio Pharma, Inc., presented new exploratory analyses from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, showing directionally favorable trends beyond growth across medical complications associated with achondroplasia, including sleep apnea, otitis media, and body composition. These data were presented at the […]
Tag: AHI
TAP Sleep Care Combination Therapy Delivers 95% AHI Reduction in Severe CPAP-Resistant OSA
TAP Sleep Care highlighted clinical evidence on Combination Therapy for CPAP-Resistant Obstructive Sleep Apnea from Martin A. Denbar, DDS, DABDSM, Diplomate of the American Board of Dental Sleep Medicine and Adjunct Assistant Professor in the Department of Internal Medicine at Texas A&M School of Medicine (Texas Dental Sleep Services). The […]
AI Identifies Previously Unrecognized Health Insights in Routine Sleep Studies
A novel AI model can use information collected during routine sleep studies to identify patients’ long-term health risks, according to a new study published in Nature Communications. Developed by a multidisciplinary research team, the model uncovered hidden sleep patterns linked to risks including heart disease, cognitive decline and death. The […]
TAP Sleep Care Publishes myTAP Case Study Showing Rapid OSA Improvement
TAP Sleep Care® announced the publication of a compelling case report demonstrating the rapid, near-complete effectiveness of its myTAP® chairside titratable oral appliance when combined with a mouth shield for nasal breathing. Case #13 titled, “Two-Night Breakthrough in Treatment-Resistant OSA: Immediate-Effective Outcomes by combining Chairside OA with Mouth Shield,” authored […]
Wesper to Unveil First Multi-Tier Sleep Diagnostic Ecosystem for Personalized Sleep Care at SLEEP 2026
Wesper unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right […]
LivaNova Receives U.S. FDA Premarket Approval for aura6000 System to Treat Moderate to Severe OSA
LivaNova PLC announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with […]
Sunrise’s AI-Powered Measure of Respiratory Effort, REMOV, Better Reflects OSA Symptoms Than Traditional PSG Metrics
Sunrise Group, a pioneer in medical device innovation and sleep care announced a new peer-reviewed study in Nature Communications Medicine. Sunrise developed the only home sleep test with respiratory effort measurement that has been validated against esophageal pressure, the reference standard. The study reveals that REMOV, the Sunrise-specific marker of […]
A New Piece of the Puzzle
For the millions of people managing both obesity and obstructive sleep apnea (OSA), tirzepatide (Zepbound® and Mounjaro®, Eli Lilly and Co.) may offer a welcome approach to help reduce symptoms and improve overall health and quality of life. It’s been almost exactly a year since investigators of the SURMOUNT-OSA trial […]
Belun Introduces New Features & Innovations in Sleep Monitoring
Belun is excited to share some important updates to the Belun Sleep Platform, designed to bring more insights and improved interface for clinicians and researchers in sleep medicine. The latest update introduces trend-plotting capability for patient data, allowing you to: Track longitudinal changes in sleep and physiological data; Visualize patient treatment progress over time; Support clinical decision-making […]
Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
Inspire Medical Systems, Inc. published Inspire V clinical outcomes data from its Singapore clinical study, as well as the Company’s limited market release in the United States, including single-site experience at two leading centers. These data will be presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical […]













